Advanced Bioscience Laboratories, Inc.

Advanced Bioscience Laboratories, Inc. (ABL), doing business as Advanced Bioscience Laboratories Inc., is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. As a foreign-owned, for-profit manufacturer of goods, ABL provides a wide range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies, academic institutions, and industry clients. The company's expertise spans biologics manufacturing, testing, storage, shipping, and quality assurance services. ABL has been awarded numerous federal contracts and grants, particularly from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), to advance the development of medical countermeasures for various infectious diseases and other health conditions.

Through its federal contract awards, ABL has provided a diverse array of goods and services to support preclinical and clinical development programs. These include cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious disease countermeasures such as HIV, influenza, and other vaccines and therapeutics. ABL has performed work for multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and National Institute of Neurological Disorders and Stroke (NINDS). The company has contributed to various programs, including HIV microbicides and biomedical prevention, pediatric drug formulation development, and cancer prevention initiatives. Notable projects include the manufacture of glycopeptide immunogen nanoparticle vaccines, development of bitter taste receptor blockers for pediatric medicines, and production of vaccines targeting frame-shift mutations in tumors. ABL's contracts typically do not have set-aside designations, reflecting its status as a large business in the federal contracting landscape.

ABL's involvement in federal grant programs has primarily been as a subcontractor to academic institutions. The company has supported grants focused on vaccine development and immunology studies. For instance, ABL has worked on a project to develop MecVax, a cross-protective subunit vaccine for enterotoxigenic E. coli (ETEC), in collaboration with the University of Illinois. Another significant grant-funded project involved toxicology studies and assay verification for a gonococcal peptide vaccine (TMCP2) in partnership with the University of Massachusetts Medical School. In these projects, ABL's role typically includes conducting toxicology studies, verifying immunological assays such as ELISAs and bactericidal assays, and providing technical expertise in vaccine development and testing.

ABL holds several Indefinite Delivery Vehicles (IDVs) with federal agencies, demonstrating its broad capabilities in biopharmaceutical research and development. A notable IDV is with NIAID for the Diagnostics Pre-Clinical Services Program, valued at $24 million, which supports in vitro diagnostic development. Another significant IDV is with NINDS for Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders, with a ceiling of $149.2 million. ABL also holds an IDV with NIAID for Resources to Advance Pediatrics and HIV Prevention Science, valued at $98.9 million, covering a range of preclinical development support services. Additionally, the company has an IDV with NCI for the PREVENT Cancer Preclinical Drug Development Program, focused on cGMP production of vaccines and biologicals for cancer prevention. These IDVs collectively demonstrate ABL's comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.